Harmony Biosciences Holdings, Inc. HRMY
33.64 USD -3.38 (-9.13%)
Nov 4, 2026, 12:07 PM EST
32.61 Day range 35.86
25.90 52-week range 43.49
- YTD
- -10.10%
- 1 year
- +9.51%
News
benzinga.com Harmony Biosciences Hldgs Q3 2026 Earnings Call Transcript Harmony Biosciences Hldgs (NASDAQ:HRMY) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Harmony Biosciences Reports Q3 WAKIX Sales Of $269M, Driven By Strong Demand With 400 Net Patient Adds; Appoints Peter Anastasiou As CEO, Effective January 1, 2027 Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorable Safety, Tolerability and Pharmacokinetic Profile Observed in Single-Ascending Dose StudyResults from Phase…
benzinga.com Harmony Biosciences Q3 EPS $0.81 Misses $1.10 Estimate, Sales $268.917M Miss $273.078M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $1.10 by 26.36 percent. This is a 25 percent decrease over earnings of…
benzinga.com Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.028B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.028 billion estimate.
globenewswire.com Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B
zacks.com Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com HRMY or ARGX: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value…
zacks.com Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
barrons.com Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences Technical indicators have turned bullish for the Barron's Investor Circle stock picks.
seekingalpha.com Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves,…
globenewswire.com Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday,…
defenseworld.net Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLC Harmony Biosciences (NASDAQ: HRMY - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports. They…
benzinga.com Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.
zacks.com HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
fool.com Why Harmony Biosciences Stock Got Mashed on Monday Investors weren't cheered by a major change in the company's leadership.
defenseworld.net Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down – What’s Next? Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $40.28, but opened at $38.34. Harmony Biosciences shares…
defenseworld.net Head to Head Review: Harmony Biosciences (NASDAQ:HRMY) versus PainReform (NASDAQ:PRFX) Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and PainReform (NASDAQ: PRFX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
investors.com Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.- benzinga.com Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target Needham analyst Ami Fadia reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $50 price target.
zacks.com HRMY vs. CSLLY: Which Stock Is the Better Value Option? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two…
zacks.com Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the…
globenewswire.com Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3…
defenseworld.net Insider Selling: Harmony Biosciences (NASDAQ:HRMY) Insider Sells $34,400.00 in Stock Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an…
defenseworld.net Kumar Budur Sells 1,800 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at…
defenseworld.net Sonoma Pharmaceuticals (NASDAQ:SNOA) & Harmony Biosciences (NASDAQ:HRMY) Critical Analysis Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the…
zacks.com Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report? Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
benzinga.com This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Consider ACMR stock: analysts' thoughts
benzinga.com Wolfe Research Initiates Coverage On Harmony Biosciences Hldgs with Outperform Rating, Announces Price Target of $60 Wolfe Research analyst Rudy Li initiates coverage on Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform rating and announces Price Target of $60.
benzinga.com Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $34 Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $29 to $34.
benzinga.com Harmony Biosciences Says New Data Supports Neurology Pipeline Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and updated analyst price targets.- benzinga.com Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50 Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.
- benzinga.com Harmony Biosciences Q2 EPS $1.28 Beats $0.94 Estimate, Sales $261.300M Beat $248.406M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $1.28 per share which beat the analyst consensus estimate of $0.94 by 36.17 percent. This is a 39.13 percent increase over earnings of…
benzinga.com Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
benzinga.com Mizuho Maintains Outperform on Harmony Biosciences Hldgs, Raises Price Target to $51 Mizuho analyst Graig Suvannavejh maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Outperform and raises the price target from $50 to $51.- benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
- benzinga.com Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFO Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a…
- benzinga.com Harmony Biosciences Hldgs Affirms Prelim FY2026 Sales Guidance of $1.000B-$1.040B vs $1.014B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms prelim FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.014 billion estimate.
- benzinga.com Deutsche Bank Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $36 Deutsche Bank analyst David Hoang maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $30 to $36.
- benzinga.com Truist Securities Maintains Hold on Harmony Biosciences Hldgs, Raises Price Target to $29 Truist Securities analyst Danielle Brill maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Hold and raises the price target from $25 to $29.
- benzinga.com Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.020B Est Harmony Biosciences Hldgs (NASDAQ:HRMY) affirms FY2026 sales outlook from $1.000 billion-$1.040 billion to $1.000 billion-$1.040 billion vs $1.020 billion estimate.
- benzinga.com Harmony Biosciences Q1 Adj. EPS $0.55 Misses $0.69 Estimate, Sales $215.400M Miss $225.227M Estimate Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.69 by 20.29 percent. This is a 46.6 percent decrease over earnings…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Harmony Biosciences Appoints Glenn Reicin CFO, Effective Immediately; Co. Reiterates 2026 Net Product Revenue Outlook Range $1B - $1.04B Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic…
- benzinga.com Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating…
- benzinga.com UBS Maintains Neutral on Harmony Biosciences Hldgs, Lowers Price Target to $36 UBS analyst So Youn Shim maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Neutral and lowers the price target from $46 to $36.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and maintains $55 price target.
benzinga.com CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com B of A Securities Maintains Underperform on Harmony Biosciences Hldgs, Lowers Price Target to $28 B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Underperform and lowers the price target from $32 to $28.
- benzinga.com Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $44 Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.